← All trials
NCT06568471
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2024
- Primary completion
- Feb 28, 2026
- Completion date
- May 31, 2026
- First posted
- Aug 23, 2024
- Last posted
- Aug 23, 2024
- Enrollment
- 210
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hasten Biopharmaceutical Co., Ltd.Lead sponsor
- Peking UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.